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The introduction of genetically-modified (GM) crops and food has generated long-
running and often polarized public debate, and so recognizing that ethical tensions exist about 
GM agriculture is undeniable. Although many commentators have reflected on public concerns 
associated with “changing nature,” possible risks from GM technologies, and the involvement of 
large multinational corporations (Thompson, 2007; Ankeny and Bray, 2018), there has been less 
attention in the scholarly literature on the role of public-private partnerships in GM research.  
This chapter focuses on public-private funding patterns and partnerships in the 
development of GM crops and foods in the Australian context over the past two decades. GM 
research and development (R&D) processes have several ethical tensions associated with them: 
one key issue is who gains or profits from GM research and products. Many people who are not 
opposed to GM research in principle fear that when private entities are involved, particularly the 
large multinationals with which GM research is frequently associated, shortcuts will be taken in 
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the name of profits, resulting in increased risks to human health and/or the environment 
associated with the work. Others question why such research is worth pursuing when the benefits 
are primarily associated with commercial needs and goals, rather than public benefits such as 
addressing global food security. More generally, there are concerns that the values traditionally 
associated with public research (such as openness, data sharing, transparency, and public benefit) 
are in fundamental conflict with those underlying privately-funded research (where commercial 
benefit and protection of intellectual property are critical). 
Australia is an ideal locale for this exploration, given that industry-funded research has 
increased significantly in recent years. Australia also provides a useful case study as it does not 
have complete bans on GM crop growth or use in the food supply (as has been the case until 
recently in parts of the EU and other parts of the world) and GM products are not widespread (as 
is the case in the US). In addition, there have not been detailed studies about public-private 
collaborations in the Australian context. Furthermore, public opinions on and regulatory 
approaches to GM in Australia remain mixed, representing various tensions that exist in attitudes 
toward GM.  
In order to shed light on the ethical tensions noted above, we use a quantitative data 
analysis of applications to the Australian regulatory authority for intentional release of a 
genetically-modified organism (GMO) to explore the actual distribution of public, private, and 
other forms of funding underlying the research, and patterns associated with types of crops and 
traits modified, in order to show that the typical patterns that have previously been found 
elsewhere are not the case in the Australian context. In addition, we develop short case studies 
based on publicly-available information, grey and published literature, and regulatory data in 
order to promote deeper reflection on the supposed public-private divide in research and to 
emphasize the need for scholars to explore the complex partnerships that often underlie GM 
research. Although a highly detailed analysis is not possible given the available data, we contend 
that the Australian setting provides a different perspective on the potential for various forms of 
public-private collaborations in GM research, as well as an excellent test bed for assessing 
effects of diverse types of funding and institutional arrangements. We use this analysis to 
illuminate some critical issues related to better understanding the tensions associated with this 





Background: GM and Public-Private Collaborations in Australia 
Early development of GM food plants in Australia occurred in step with other regions, 
including Europe and the US, although Australia created one of the earliest oversight bodies 
focused on GM based on voluntary guidelines (AAS, 1980). In 1987, the first GMO was released 
outside the laboratory (a GM agrobacterium, later commercialized as “No Gall”) and was the 
third recombinant DNA organism in the world to be field tested (Kerr, 2011; Hindmarsh, 2008). 
The first commercial release of a GM plant in Australia, a blue carnation for floriculture (Lu et 
al., 1991), occurred in 1995 (GMAC, 1996). The first GM crop, released in 1996 (GMAC, 
1997), was an insect-resistant cotton (Cousins et al., 1991) known as Bt or Ingard® cotton, and 
was developed by the Australian public agency Commonwealth Scientific and Industrial 
Research Organisation (CSIRO) using a gene owned by Monsanto and licensed by CSIRO, in 
partnership with Cotton Seed Distributors (Davidson, 2003).  
The Commonwealth Gene Technology Act 2000 came into effect on 21 June 2001 (Hain 
et al., 2002) due to increasing concern among the public and lack of adequate information to help 
people make informed decisions, perceptions that industry could not be relied upon to be 
sufficiently rigorous, and the need for transparency and a uniform regulatory system. The Act’s 
aim is “to protect the health and safety of the people, and to protect the environment, by 
identifying risks posed by or as a result of gene technology and by managing those risks through 
regulating certain dealings with GMOs” (Commonwealth of Australia, 2001, section 3). Since 
the Act, the responsibility for regulating GMO dealings has rested with the Office of the Gene 
Technology Regulator (OGTR), which primarily relies on peer-review processes performed by 
professional scientists. The Act explicitly excludes economic and social arguments, despite calls 
from critics to revise the legislation to require their consideration during licensing (Wickson, 
2007; Hindmarsh, 2008). Other scholars have criticized the required scientific assessment as too 
narrow in scope, arguing that the definition of the “environment” does not include ecosystem 
analysis (Lawson, 2002), and that the system facilitates approval of GM foods that is too rapid 
(Levidow and Carr, 2000) and thus is regulation for industry than regulation of industry (Lockie 
et al., 2005). 
Australia is currently ranked twelfth in the world in terms of the area of land sown with 
GM crops (ISAAA, 2016), particularly cotton and canola. However, as compared to other 
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countries (such as the US), relatively few GM crops have been approved for commercial release; 
the total number of applications made to the OGTR for licenses on an annual basis is small. 
Nonetheless, GM crops remain a highly controversial issue in Australia. Shortly after OGTR 
approval of the commercial release of InVigor® canola in 2003, bans on growing GM food crops 
were established in canola-growing states. These moratoria have been attributed to various anti-
GM campaigns and state-based political issues, including concerns about the potential economic 
impacts of GM canola on Australia’s access to export markets where GMOs are not permitted or 
are greatly limited, such as Japan and the European Union (Hindmarsh, 2008; Tribe, 2012). By 
2010, GM canola was permitted (with some restrictions) in most states. Currently, general bans 
only persist in Tasmania and South Australia (where the moratorium was recently extended to 
2025).  
Australians are generally considered to be less cautious about GM than Europeans and 
more hesitant than those in the USA. Yet, most studies of Australian consumers have found that 
attitudes to biotechnology in food production, including GM foods, tend to be more negative 
than positive (Bray and Ankeny, 2017) and the adequacy of GM food labelling in Australia is 
contested (Bray and Ankeny, 2015). Moreover, previous qualitative research has shown that the 
purpose for which GM is used and who will benefit from it are critical to Australian consumers’ 
views on GMOs (Ankeny and Bray, 2016). Direct anti-GM activism has been far more limited in 
Australia compared to Europe or the USA; the 2011 destruction of a CSIRO field trial of GM 
wheat with altered nutritional value represents an extreme form of protest for Australia 
(described below in case study 2). Popular concern continues about the use of GM in crops 
destined for the food supply and the potential for drift between GM and non-GM crops 
(especially organics), highlighted in a recent court case in Western Australia (Neales, 2013).  
GM research originally has occurred within an innovation system in Australia that was 
historically characterized as having a “low level of science and technology expenditure, a high 
level of government involvement in financing and undertaking research, a low level of private 
sector research and development and exceptionally high dependence on foreign technology” 
(Gregory, 1993, p. 324). Efforts were made in the 1990s and early 2000s to increase industry 
contributions to academic research, via tax and other incentives for collaborative research 
(Collier, 2007). For instance, the Australian Cooperative Research Centres (CRCs), which began 
in 1990, are multisite collaborative R&D ventures bringing together university and public-sector 
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research and promoting the flow of knowledge and technical skills between private industry and 
public organizations (EOAS, 2011). The 2001 Commonwealth package Backing Australia's 
Ability provided significant support for the commercialization of research conducted in 
universities and publicly‐funded research agencies. The National Competitive Grants Program of 
the Australian Research Council (ARC) instituted Linkage schemes in the early 2000s which are 
intended to encourage collaborative research especially with industry. Despite these efforts, 
Australia is still claimed to underperform based on most measures of collaboration 
(Commonwealth of Australia, 2010). 
 
 
Conflicts Created by Public-Private Collaborations?  
Traditionally, academic and industrial/commercial research has long been interdependent. 
However, recent commentators have decried the negative influences of industry on academic 
science, which they see as having increased in recent times. Indeed, contemporary critiques 
contend that partnerships between industry and universities have become more varied, 
aggressive, and publicly visible, and wider in scope in recent years (e.g., Lacy et al., 2014).  
Although considerable resources are necessary to pursue many forms of modern research, 
money from industry often is viewed with suspicion even by scientists themselves (Biscotti et 
al., 2009). Criticisms range from potential to compromise the research problem choice and 
priority setting, to falsification or suppression of research results to suit commercial interests, 
particularly in the biomedical sector (e.g., Krimsky, 2003; Sismondo, 2008; Elliott, 2010). Some 
contend that the internal norms of academic science and commercial research are in principle 
incompatible (e.g., Blumenthal et al., 1996; Slaughter and Leslie, 1997; Krimsky et al. 1999; 
Bok, 2003), as profit motivations necessarily run counter to traditional academic values 
associated with scientific inquiry and free flow of knowledge and information (e.g., Hackett, 
2005). Others contend that these arguments require a blind adherence to existing systems without 
adequately considering that industry-academia-governmental, or so-called “triple helix” 
(Etzkowitz and Webster, 1998), collaborations may represent new modes of knowledge 
production (Gibbons et al., 1994). More recently, scholars have noted that the boundaries 
between academic and commercial research are no longer fixed or rigid, as these domains are 
increasingly interwoven especially in medical and agricultural biotechnologies (Vallas and 
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Kleinman, 2008; Kleinman, 2010). Thoughtful scholarship has emerged about this interplay as 
well as potential regulatory and other forms of solutions (e.g., Radder ed., 2010). 
Agricultural biotechnology is relevant for general debates on public-private 
collaborations in science, because agriculture was one of the earliest fields that attracted 
significant commercial investment (Busch et al., 1991). Agricultural biotechnology has also 
traditionally received considerable public investment in the US, Australia, and elsewhere, with 
substantial efforts to attract industry funds for research collaborations (Mowery et al., 2004). Our 
springboard for this chapter’s analysis is Welsh and Glenna’s (2006) study showing that US 
university research on transgenic crops has increasingly mirrored the research profile of for-
profit firms during the period 1993-2002 and that private sector firms have dominated R&D and 
commercialization processes for GM. Welsh and Glenna conclude that these trends have led to a 
narrowing focus on a few commercially-important crops with plant-protection traits such as 
herbicide tolerance (HT) and insect resistance (IR). The reason is because these allow for 
substantial returns on R&D investments (Ervin et al., 2001) and are linked to agricultural inputs 
produced and sold by the same companies (e.g., glyphosate-based herbicides). In contrast, critics 
note that staple food crops (FAO, 2004) and other traits, such as those with environmental or 
nutritional benefits, have been relatively neglected, especially during the early years of GM 
research. Some argue that to correct this situation, the public sector must pursue a greater share 
of transgenic crop development via direct funding or financial incentives, with emphasis on traits 
associated with publicly-valued benefits (e.g., Doering, 2004), or even less commercially-
relevant or subsistence crops, sometimes termed “orphan” crops (e.g., Paarlberg, 2000).  
In addition, Lacy and collaborators’ recent survey (2014) of US university and industry-
based scientists and others participating in agricultural biotechnological research collaborations 
identified concerns over their “distinct cultures” with different values and goals, understandings 
of their research environments, and criteria for research agenda choice. Although their one 
shared criterion for problem choice was the public good, it is noted that underlying this concept 
might be fundamentally different ideas, given that non-profit organizations such as universities 
have different responsibilities and goals than profit-making institutions (Mansbridge, 1998). In 
order to minimize conflicts and maximize the potential for complementary efforts in 
collaboratory work, the Lacy et al. recommend closer monitoring of the nature, goals, and 
outcomes of these relationships; stronger and more creative policies and practices to enhance 
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university interactions with the private sector while protecting the autonomy and freedom of 
academic scientists; and adequate public agricultural research funding. 
 
 
Data Analysis of GM Research in Australia 
We use publicly-available data to elucidate general patterns over the past 15 years in GM 
research in Australia, in order to address questions about the dominance of private funding in 
GM research. Australia’s OGTR’s public website provides a constantly-updated table 
summarizing all applications and authorizations (licenses granted) for intentional release of 
GMOs into the environment, whether controlled (e.g., as part of a field trial) or released. 
Although the majority of applications and licenses have been for agricultural and horticultural 
crops, applications for viruses and vaccines are also listed in the OGTR’s table (though excluded 
here as we focus on crops). While numerous organizations may have been involved in the R&D 
processes leading to the point of making an application, only the name of the license holder 
conducting the GMO dealings typically is supplied to the OGTR.  
Our analysis of the GM research landscape focuses on key factors that have been 
discussed in the existing scholarship: the type of organization holding the license, the species or 
crop, and the trait(s) modified. From the time that OGTR licensing began in Australia in 2002 
until 2017, 124 authorizations for Dealings involving Intentional Release (DIRs) for plants used 
in agriculture and floriculture have been granted to 25 different licensees. Applications for DIRs 
withdrawn prior to OGTR assessment or still pending, and applications for vaccines are excluded 
from our analysis. Table xx.1, which depicts the distribution of applications for DIRs by entity, 
shows that the division of private and public licensees is roughly equal. “Private” entities, 
including subsidiaries of international corporations such as Monsanto Australia Ltd., small, 
home-grown companies, university spin-offs, and industry-owned companies funded by statutory 
levies (e.g., Sugar Research Australia Ltd) hold or have held 63 out of 124 licenses (51%). 
“Public” entities, including universities and federal and state government agencies and research 
bodies, hold or have held the remaining 61 out of 124 licenses (49%). 
 
Table xx.1: Applications for DIRs by Entity (‘other public’ and ‘other private’ are groupings 




CSIRO 30 Monsanto Australia 22 
Vic DPI/DEDJTR 8 Bayer CropScience 13 
University of Queensland 7 Sugar Research Australia/BSES 5 
Qld University of Technology 6 Florigene 5 
University of Adelaide 4 Dow AgroSciences 3 
WA Dept Ag 3 Hexima 3 
Other 'public' 3 Pioneer Hi-Bred Australia 2 
  Grain Biotech Australia Pty Ltd 2 
  Nuseed Pty Ltd 2 
  Other 'private' 6 
Total 61 Total 63 
 
 
Eighty-eight licenses have been granted for dealings with what are considered globally as 
major crops: cotton, canola, wheat (sometimes combined with barley in a license), rice, and 
maize (although rice and maize are not considered major crops in Australia). Of these licenses, 
49 are currently or have been granted to private entities. As shown in Table xx.2, two are for 
wheat, 14 for canola, and the overwhelming majority for cotton (33). Public sector licenses for 
the major crops, differ in their distribution: of 39 granted, 19 are for wheat and wheat/barley 
together, 17 for cotton, and one each for canola, maize, and rice. Overall, cotton licenses far 
outnumber wheat/barley and canola combined, with a total of 50 public and private granted, 
constituting the greatest proportion of DIR license applications. One company, Monsanto 
Australia Ltd, has held 22 licenses for either cotton or canola. The only organization which has 
held a greater number of licenses during the period of study is the CSIRO, with 30. CSIRO’s 
licenses include 15 for cotton, but also cover a range of other crops such as wheat/barley, 
grapevine, poppy, maize, rice, and safflower. 
 
Table xx.2: Crops in DIRs from Public and Private Entities 
Public Private 
Cotton 17 Cotton 33 
Wheat 10 Canola* 14 
Wheat and barley 9 Wheat 2 
Canola 1   
Rice 1   
Maize 1   
Total “major crops” 39 Total “major crops” 49 
    
Banana 5 Sugarcane 5 
Sugarcane 4 Indian mustard (only) 2 
Pineapple 2 Carnation 2 
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White clover 2 Rose 2 
Papaya 1 Torenia (bluewings flower) 2 
Oilseed poppy 1 Safflower 1 
Poppy 1   
Narrow-leafed lupin 1   
Perennial rye and tall fescue grass 1   
Grapevine 1   
Potato 1   
Safflower 1   
Sorghum 1   
Total “minor crops” 22 Total “minor crops” 14 
Total 61 Total 63 
*two of the private Canola applications include Indian mustard 
 
Comparison of these results with the breakdown for minor crops, which include “orphan” 
crops such as cassava, some legumes and course varieties of millet, and which are defined by 
Bender (2013) as those consumed by poorer populations for which there is little commercial 
market, shows a strong contrast: 17 different ‘minor’ crops are represented, including sugarcane, 
safflower, rice, lupin, and carnations. Of the 36 licenses granted for these crops, private entities 
hold 14, but for only six types of crops: three types of flowers modified for qualities such as 
color (6 licenses), sugarcane (5 licenses), Indian mustard (2 licenses, in addition to the 2 
applications combined with canola), and safflower developed for industrial (i.e., non-food) 
purposes (1 license). Of the remaining minor crops, public entities have applied for 22 licenses 
for 13 crop and pasture species. This data provides evidence for the patterns observed elsewhere: 
private, commercial entities unsurprisingly tend to focus on commodities with significant 
potential for profit. Nevertheless, it also reveals that diverse crops with different purposes and of 
importance in diverse regions of Australia are represented in GM licensing. 
Regarding the claim that private sector resources tend to be concentrated on plant 
protection traits, particularly insect resistance (IR) and herbicide tolerance (HT), licensing data 
shows this pattern also tends to hold in Australia, as shown in Table xx.3. Many licenses include 
multiple traits, some containing as many as six, and the majority containing two or three. The IR 
and HT traits are by far the most common inclusions in licenses held by the private commercial 
entities which far outnumber those held by the public entities for the same traits; 36 of 42 (86%) 
DIRs which include HT are (or have been) privately held and 27 of 35 (77%) for IR. The picture 
differs when considering other types of traits, including modifications related to yield, abiotic 
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stress tolerance (e.g., drought or salinity tolerance, extremely important traits in the Australian 
context), human food composition (e.g., nutrition-related traits), animal nutrition, and disease 
resistance; licenses including these traits are held mostly by public entities. 
 
Table xx.3: Traits in DIRs from Public and Private Entities. If a GMO contains more than one 
trait, it is listed in all relevant categories; selectable markers or reporter genes, promoters, and so 
on are not categorized here. 
Public Private 
Yield 14 Herbicide tolerance 36 
Abiotic stress tolerance 13 Insect resistance 27 
Composition - food (human nutrition) 13 Abiotic stress tolerance 6 
Disease resistance 8 Hybrid breeding system 6 
Insect resistance 8 Modified colour 5 
Herbicide tolerance 6 Plant development 4 
Composition - food (processing) 5 Composition - animal nutrition 2 
Product quality - food 5 Composition - food (human nutrition) 2 
Composition - non-food 4 Composition - non-food 2 
Plant development 4 Disease resistance 2 
Composition – animal nutrition 2 Yield 2 
Product quality – non-food 1 Bioremediation 1 
Total 83 Total 95 
 
 
 In summary, this analysis of OGTR publicly-available data shows active involvement of 
both the public and private sectors. Unlike the US situation (e.g., Walsh and Glenna 2006), 
private entities arguably do not “dominate” GM R&D in Australia, given the 49% public-51% 
private split. The general patterns of focus on certain types of crops and traits in DIRs granted to 
private versus public entities does appear to parallel those found elsewhere. Although 
commercially-important crops and traits have been prominent especially for private entities, we 
find evidence of minor and “orphan” crops and inclusion of non-plant protection traits in the 
public projects; however based solely on the quantitative assessment above, it is clear that staple 
food crops in fact have been relatively neglected.  
However, this type of data obscures a range of complexities that must be considered 
when analyzing patterns in GM research. Some research entities are decidedly hybrid, since they 
are considered as commercial/private entities but they rely on statutory levies and hence have 
certain accountabilities to their stakeholders that mirror responsibilities held by public entities. 
Most importantly, the publicly-available data do not show the extent and nature of research 
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partnerships and collaborations amongst and between the public and private sectors since (as 
noted above) only the name of the license holder conducting the GMO dealings typically is 
supplied to the OGTR. Additional organizations or companies, which may have been involved in 
the R&D processes leading to the point of making an application, are not available in the public 
summary data (or often not present explicitly in the licensing documentation). This apparent 
simplicity of origin obscures the fact that the processes of getting a GMO to where it can be 
assessed by a regulatory body such as the OGTR is extremely likely to have involved input—
financial, technical, material, or otherwise—beyond that of the named applicant. We have no 
reason to assume that who is listed as the applicant is biased in any particular direction, but we 
note that to perform a full quantitative analysis of the balance and breadth of interests engaged in 
GM R&D in Australia would require additional source materials, many of which would be 
difficult to access given they are likely to be considered commercial-in-confidence.  
Hence in the next section, we present three brief GM case studies from the Australian 
context to explore key issues arising and underlying complexities associated with this type of 
research: (1) drought-tolerant wheat, (2) high-amylose wheat; and (3) Vitamin A-enhanced 
“super banana.” Not all of these cases were unmitigated successes in commercial terms or with 
reference to public benefits, but we contend that the mixture of outcomes represented is 
reflective of typical processes in this domain. We selected these cases because they all involve 
traits that arguably are associated with the public good in the broad sense, though of course there 
also is potential for commercial profits in some cases. We also do not intend our choice of these 
case studies to be construed as endorsement of them, particularly as they have not been without 
controversy (as we discussed below), but we use them as a springboard for discussion and 
reflections about future research questions that should be pursued to further illuminate various 
tensions that exist in this domain. 
 
 
GM Case Study 1: Drought-Tolerant Wheat 
Wheat is the dominant grain crop in Australia and one of its most valuable agricultural 
exports, second only to beef in 2015 (Xue et al., 2017). According to Wilson et al. (2015), there 
has been a recent resurgence in GM wheat research, especially in the US and Australia, 
following suspension of earlier attempts to commercialize GM wheat due to grower and 
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consumer opposition in Canada and the USA (Eaton, 2011; Kinchy, 2012). In 2004, Monsanto 
withdrew applications for commercial release of its GM wheat in various countries, including 
Australia (Schurman and Munro, 2010; ISAAA, 2018).  
Among the most common traits targeted for GM are those for tolerance to abiotic 
stressors such as drought, salinity, and frost; ten of the 21 (48%) of the wheat (or wheat/barley) 
DIRs issued by the OGTR since 2005 include drought-tolerance traits, with other traits being 
pursued including enhanced yield, improved nutrient use efficiency, improved grain quality, and 
altered grain composition (OGTR, 2018). The focus on drought tolerance is unsurprising, given 
that heat and drought stress are having considerable impacts and are considered to be the major 
challenges to future wheat production in Australia and many other grain-producing regions 
(Hopkins, 2009; Langridge, 2012). Although breeding for drought tolerance in wheat by 
conventional methods has been practiced for decades, only “modest gains” are said to have been 
achieved thus far (O’Neill, 2010). 
In 2006, BASF Plant Science, a plant biotechnology subsidiary of the German chemical 
company BASF SE, announced an approximately A$28 million investment in a project to 
develop drought-tolerant wheat in Australia, spanning seven years and involving 25 scientists 
based at the publicly- and industry-funded Australian Molecular Plant Breeding Cooperative 
Research Centre (MPBCRC) (MPBCRC, n.d.; Hopkins, 2009). First established at the Waite 
Campus of the University of Adelaide in July 1997 as the Cooperative Research Centre for 
Molecular Plant Breeding, and intended to benefit the crop and pasture industries, the Centre 
received a further seven years’ funding under the Commonwealth Government’s CRC Program 
in July 2003, continuing in a new location in Victoria as the MPBCRC (which was disbanded in 
June 2010). A document produced by the MPBCRC (n.d.) during this period listed six core 
partners in the CRC (not just the wheat program), including the Victorian Government’s 
Department of Primary Industries (now the Victorian Government Department of Environment 
and Primary Industries, and hereafter DPI Vic) and ten commercial and industry partners, 
including BASF, along with its federal government funding.  
The gene candidates for the desired trait of drought tolerance were derived from plants 
(maize and thale cress), a moss, and a yeast (Australian Grain, 2007), and were provided by 
BASF Plant Science (along with genes related to yield increase and resistance to fungal 
diseases), with MPBCRC providing “expertise and a patented technique for developing highly 
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effective genetic modifications of wheat” (MPBCRC, n.d., p. 9). Rights to commercialize any 
products resulting from the project were to be held by MPBCRC for Australia, New Zealand, 
and some countries in the developing world, namely those countries assisted by the International 
Maize and Wheat Improvement Centre (CIMMYT) in Mexico, a non-profit research and training 
organization with over 500 partners in 100 countries and another core participant in MPBCRC 
(CIMMYT, 2016; MPBCRC, n.d.). BASF was to handle commercialization elsewhere 
(MPBCRC, n.d., p. 10).  
Although the publicly-available information summarized above shows that the research 
processes prior to application were collaborative efforts between numerous public and private 
entities under the umbrella of MPBCRC, officially the DIRs were granted by the OGTR to the 
DPI Vic for the initial GM wheat trials of relevance in 2007 and 2008. DIR 071/2006 permitted 
trials of GM wheat with drought-tolerance genes, the first such trial in Australia, during the 2007 
and 2008 growing season, with DIR 080/2007 covering trials from July 2008 to March 2010 
involving new GM lines and continued research on previously approved lines (OGTR, 2016). 
Following “very promising” field trials over the two licensing periods, the MPBCRC’s then-
Chief Executive, Dr. Glenn Tong, stressed the need for a cautious approach to interpreting the 
preliminary results, with many field trials yet to come (Hopkins, 2009).  
When MPBCRC ceased operating in in June 2010, DPI Vic was expected to continue 
with the GM wheat program (O’Neill, 2010); whether this research extended beyond the 
monitoring phase of the trials in question is unknown. Agriculture Victoria Services Pty Ltd—a 
private company wholly held by the Victorian Government—is responsible for the 
commercialization and protection (including intellectual property) of novel technologies created 
by the Agriculture Victoria Research Division, into which DPI Vic was recently rolled. Both 
licenses were surrendered in March 2016; drought-tolerant GM wheat has yet to be 
commercialized, with no DIRs pending.  
 
 
GM Case Study 2: High-Amylose Wheat 
Genetic modification for traits offering potential public health benefits is another area of 
crop research, which can fall in the realm of “public good.” This case examines a wheat 
developed to be high in amylose, a type of resistant starch or functional form of dietary fiber, 
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which is already present in wheat and other whole foods, but which is lacking in typical modern 
diets (Braidotti, 2016). Increasing the level of resistant starch in wheat, a staple grain, was 
pursued due to its potential contributions to promoting digestive health, fighting Type 2 diabetes, 
and reducing the risk of bowel cancer, without requiring behavioral changes (Regina et al., 2015; 
CSIRO, 2017).  
High-amylose GM wheat was developed by Arista Cereal Technologies, an Australian-
French, public-private joint venture announced in 2006 by the Australian research bodies CSIRO 
and the Grains Research and Development Corporation (GRDC), and the French-based company 
Limagrain Céréales Ingrédients (LCI) (CSIRO, 2017). LCI is a subsidiary of the French seed 
company Limagrain, an international farmer cooperative or grower-owned corporation 
(Limagrain, n.d.) which “develops and manufactures authentic and functional cereal ingredients 
for manufacturers in the food industry” (LCI, n.d.). Arista was created to allow research, 
development, and commercialization of a high-amylose wheat suitable for processing, utilizing 
genetic technologies developed by CSIRO’s Plant Industry division and Biogemma UK Ltd, a 
European plant biotechnology company of which Limagrain is a shareholder. Biogemma was 
founded in 1997 by seed companies and French field crop producers, and shareholders include 
seed and agricultural finance companies and a French arable crops R&D institute (Biogemma, 
n.d.). The GRDC is a statutory corporation founded in 1990 to undertake research, development, 
and extension on behalf of Australian grain growers as well as for the benefit of industry and the 
public more widely. Primary financial support to the corporation comes from two sources: a 
grower levy based on the net farm gate value of the annual production of 25 grain, pulse, and 
oilseed crops, and an Australian government contribution, annually determined and based on the 
three-year rolling average of the gross value of production of the 25 leviable crops (GRDC, 
2018).  
A team composed of plant geneticists, agronomists, and human nutritionists including 
researchers affiliated with CSIRO’s Food Futures National Research Flagship as well as 
Biogemma UK Ltd. used a combination of GM and conventional breeding techniques to create 
wheat with the desired qualities (Regina et al., 2006; Braidotti, 2016). It was hoped that the use 
of some conventional techniques might make the wheat more acceptable to consumers; however 
despite early optimism (e.g., Patton, 2006), a clear pathway to regulatory and consumer 
acceptance of GM wheat has not readily emerged (see Salleh, 2006). 
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Following successful animal feeding trials, human nutritional studies of the high-amylose 
wheat were planned. However, activists from environmental organization Greenpeace destroyed 
the first outdoor trial of the CSIRO GM wheat near Canberra in July 2011; this crop was 
intended to be used in the first human studies (ABC, 2011). Greenpeace (2011, n.p.) claimed that 
CSIRO’s involvement in the project represented a conflict of interest: 
The web of public-private partnerships that sits behind these research programs is 
misleading and makes it challenging for the public to know where and to whom their 
tax dollars are being spent. This lack of transparency makes it difficult for the public 
to exercise its right to hold the government to account. This difficulty is exacerbated 
by the secrecy surrounding government documents related to GM plants. 
Greenpeace’s Freedom of Information request for documents about the commercial 
partnership between CSIRO and Limagrain was refused. The documents are 
“commercial in confidence”. Australian taxpayers cannot properly exercise their rights 
to hold the government to account under these conditions. 
Arista owns the intellectual property associated with this project and issued the first license for 
the high-amylose trait to an American milling company in 2016, with LCI as their partner in 
breeding the trait into locally-adapted wheat varieties (Bay State Milling, 2017). The first crop of 
enhanced (but non-GM) wheat, grown in Idaho, Oregon, and Washington, was harvested in 2017 
and was to be milled into trademarked high-fiber wheat flour (CSIRO, 2017). Royalties would be 
paid per hectare of wheat grown, in principle providing a return on the funding originally 
allocated though funding of the GRDC by farmer levy and taxpayer funding of the CSIRO 
(Neales, 2017).  
As for the potential future of high-amylose wheat in Australia, it was recently stated that 
Arista was partnering with a breeding company to develop high-amylose wheat varieties suitable 
for different regions, and working on ways to produce enough grain for product testing and seeds 
for initial commercialization. Lindsay Adler from CSIRO and an Arista Director stated that the 
company was keen to find an Australian licensee who would develop a new product for local and 





GM Case Study 3: Vitamin A-Enhanced Banana 
Our third case also concerns the development of a crop with a modification that meets a 
public health need, a vitamin A-rich banana. One of the world’s top ten food crops by production 
(Paul et al., 2017), various types of bananas are widely grown in wet tropical and subtropical 
regions for consuming fresh or cooking, with 85% of production worldwide consumed 
domestically. In many banana-growing regions, cooking bananas are principal staple foods 
(particularly in rural areas) as well as subsistence crops; in some regions of Africa and Asia, they 
also are the major source of dietary starch (Dale et al. 2017a).  
Described by lead researcher James Dale as a “significant humanitarian project” (QUT, 
2017), research on the biofortified banana has been underway since at least 2005. 
Biofortification is the process of increasing the levels of essential nutrients, especially in staple 
foods, by conventional plant breeding techniques or genetic modification (Dale et al., 2017a; 
Bender, 2013). Similar to the widely-publicized (and highly controversial) GM Golden Rice, the 
enhanced banana, also orange-fleshed due to its provitamin A (beta carotene) content, is seen as 
a way to combat vitamin A deficiency, which despite various public health initiatives is still a 
major problem particularly in parts of Africa such as Uganda and in Southeast Asia. In addition 
to the public health aspect of the project, the banana will be engineered to be disease resistant 
and will be freely available if commercially approved: “No patents, breeders/variety rights, or 
commercial rights have been or will be claimed on the pro-vitamin A genes or trait. There will be 
no technology fees associated with applying the technology in Uganda or elsewhere, nor will 
there be any additional cost to farmers” (Banana21, 2016, n.p.).  
Related GM research has focused on generating resistance to a virulent fungus commonly 
found in Cavendish bananas (known as Panama disease). Cavendish bananas constitute over 
40% of world production and virtually all the export trade in bananas. Virus resistance research 
has been funded via the ARC Linkage program (LP110100186), in partnership with researchers 
in the USA, the Netherlands, and the Darwin Banana Farming Company, and an Australian 
banana wholesaler, LaManna (Dale et al., 2017b). This project provides a good example of 
“open research,” inasmuch as the researchers have communicated about and involved local 
banana growers in the research, particularly given the economic importance of bananas in 
Queensland, where the research institute is located and trials were to occur. 
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Prior to receiving support from the private Bill & Melinda Gates Foundation (BMGF) for 
the biofortified banana research, researchers at the Centre for Tropical Crops and 
Biocommodities at Queensland University of Technology (QUT) were working with Ugandan 
researchers from the National Agricultural Research Organization. They made a successful bid 
for their Vitamin A banana project in response to a 2004 call from BMGF for expressions of 
interest regarding solutions for the “Grand Challenges in Global Health” initiative, including the 
development of micronutrient-rich staple crops (Fresh Fruit Portal, 2013). In 2005, BMGF began 
supporting the project, now one of the genetic improvement projects under the umbrella of the 
“Banana21” collaboration between scientists at QUT and their Ugandan counterparts, and were 
joined by the UK Government Department for International Development in 2012 for Phase 3 
(Banana21, 2016).  
Following initial laboratory work, field trials began in Queensland in 2008 (which also 
was the first trial of GM bananas in Australia), with QUT obtaining licenses for controlled 
release. The intention was to transfer the resultant technologies to Uganda for incorporation into 
the local cultivars and for further field trials (which began there in 2010), and for selection and 
eventual release there and in other African countries with similar needs (QUT, 2014). However, 
when approval for human trials in the USA was announced in 2014, controversy arose with 
protests outside the BMGF headquarters in Seattle and elsewhere. Thus the trials were delayed, 
not only because of the protests but also because it was found that transporting the fruit was 
difficult, with no public announcement available about their completion. Uncertainty also has 
surrounded the process of approval for commercial release of the banana in Uganda: although 
there now is a regulatory framework for obtaining licenses for GM crop trials, a bill to expand 
the framework to include GMO release which was approved by Parliament in late 2017 is yet to 
be signed by the Ugandan president; no GM crops have been approved for commercial sale to 
date. Therefore, early predictions regarding the release date of the banana have been pushed back 




While these case studies are admittedly selective, combined with the quantitative analysis 
presented above they illustrate forms of collaborative research that have largely been overlooked 
18 
 
in existing analyses of public-private partnerships, and they reveal different types of funding 
patterns than conventional collaborative partnerships, involving governmental entities and 
programs emphasizing both commercial and public benefits. In addition, they encourage us to 
consider less restricted definitions of “public benefit.” These points taken together underscore 
that the potential sources of ethical tensions and conflicts about GM research typically discussed 
in popular and scholarly literature, notably the undue influence of industrial interests, may need 
to be reconsidered or at least situated in a much more complex context. 
At least in Australia, the partnerships that underlie current GM research are complex 
webs that, ironically, have frequently been criticized by GM opponents (e.g., by Greenpeace). A 
key takeaway from our analysis is that many projects involve public entities and private 
companies and include not only large multinationals but also locally-based start-ups and 
transnational collaborations; the latter examples might not be surprising given that most 
Australian companies are relatively small (Dodgson, 2011). In addition, some of the projects 
involve non-governmental organizations (NGOs) as well as farmer-associated organizations. 
Importantly, current analyses of GM research tend to exclude these types of partners, because 
they have limited presence in the US, where most previous analysis has occurred, or because 
they have emerged more recently than the periods covered in previous scholarship. Overlooking 
projects involving these other types of partners and alignments could indicate an overemphasis 
on projects aimed at profits and other benefits not primarily aligned with the public good. They 
also may obscure the fact that some products that might appear to be primarily commercial or 
economic may contribute to the public good when defined more broadly. For instance, traits that 
provide environmental benefits also are likely to benefit farmers economically by making crops 
better adapted to the extreme conditions in Australia. In addition, many projects in this survey 
were funded not just via university-industry partnerships, but involved governmental funding 
schemes, such as the CRCs and ARC Linkage programs, as well as NGOs, all of which have 
mandates to create public goods, but in many cases also use commercial activities to partially 
fund ongoing and future research. 
This analysis suggests the need to reconsider what counts as public benefit. Narrowly 
construed, “public benefit” is often taken to be equivalent with promoting global food security, 
parallel to the values promoted via the Green Revolution, in contrast with the “gene revolution” 
associated with GM (e.g., Parayil, 2003; FAO, 2004). However, the range of GM crop types 
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pursued in the Australian research context is broad, with diverse goals within each project. Many 
of these are well-aligned with public needs and benefits, particularly associated with reducing 
environment impacts and growth of crops in extreme climatic conditions. It even may be 
contended that Australia has a distinct role to play in the pursuit of GM research aimed at public 
benefit given its unique qualities. For instance, Australia is the only “officially recognized 
Developed Countr[y]” with a tropical region area (Banana21, 2016), and therefore the only one 
with a tropical agriculture industry; hence it is well placed to develop various types of bananas 
that can have benefits in less developed regions and distributed in ways that are not 
commercialized (the question remains of course about whether these types of initiatives are 
appropriate in other terms, but this concern is not our primary focus in this chapter). The 
presence of projects including traits other than those associated with plant protection raises 
questions about fears that private agendas are swamping out other types of R&D priorities in GM 




It is clear that there are various types of tensions at work surrounding GM agriculture. A 
particularly important tension involves what role industry and other non-public entities should 
play in the development of GM technology and how the distribution of benefits should be 
decided. The examples presented here from the Australian context do not show or suggest that 
any or all GM research is good, or worth pursuing or supporting. There are numerous factors that 
need to be considered to develop a definitive analysis of the impact of GM research to date and 
future potential (or lack thereof). Instead, our contribution provides empirical information on the 
current state of play that allows us to widen our dialogue about these issues. Along with Vallas 
and Kleinman (2008), we contend that biotechnology (and GM research in particular) is a 
domain 
marked by an increasing commingling of normative codes and practices from two 
previously relatively distinct institutional domains, leading to the emergence of a 
knowledge regime that is fraught with tension, contradiction and inconsistency… Far 
from demanding resolution, such tensions can in fact serve as a source of creative 
dynamism, dialogue and reflexivity, compelling the various parties to justify their 
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assumptions, to engage in dialogue with those whose orientation differs from their 
own and thus to make possible a deeper and more innovative understanding of the 
major tasks at hand. (p. 306) 
As Vallas and Kleinman note, rather than viewing these complexities and tensions as difficulties, 
we should treat them as assets particularly because of their ambiguity (see also Stark, 2001).  
Our study highlights future research topics to be pursued in order to enrich our 
understanding of the tensions underlying GM research and domains facing similar issues. First, 
due to the limitations of the existing quantitative data, more up-to-date, qualitative evidence 
should be gathered about how priorities are set, including the potential for increasing public 
engagement and participation in decision-making, and how research is structured, especially with 
regard to access to products, intellectual property arrangements, and so on. Admittedly, this type 
of approach may be limited due to commercial-in-confidence considerations, but this potential 
difficulty is not sufficient to warrant ignoring these issues. Second, more exploration is needed of 
scientists’ views on how they fulfil their “social license” (Raman and Mohr, 2014) and assess 
and respond to public priorities and needs, particularly in the Australian case given the OGTR’s 
lack of mandate in this regard. Finally, GM research has taken hold in numerous less high-profile 
locales, and collaborative practices in South America, Canada, Eastern Europe, and Asia are 
worthy of more scholarly analysis than has occurred to date. 
Our analysis also shows that ignoring funding arrangements for the development of GM 
crops to a public-private binary obscures the complex networks and types of arrangements that 
are typical of contemporary science. It could be argued that the funding arrangements for the 
development of GMOs are less important to consider than evaluating how the GMO will be 
deployed within food production systems, neoliberal or otherwise, how these arrangements are 
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